Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma

2026-525406-36-00 · tracked via the Priya Life Science EU tracker

Sponsor

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Neoplasms

Decision date

02/09/2026

Enrollment target

Sites

Italy

Condition studied

Adrenocortical Carcinoma

Investigational medicinal product(s)

THIOSULFATECISPLATINDOXORUBICIN

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

The percentage of patients with local or peritoneal disease recurrence within 36 months after surgery.

Endpoint detail

Percentage of patients with major perioperative morbidity (grade > 2 according to the Clavien-Dindo classification of surgical complications)., Postoperative mortality rates at 30 and 90 days., Disease-specific survival up to 3 years after surgery.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525406-36-00 on CTIS ↗ ← All trials in the EU